Scroll Back to Top

 

Join us at AACR Annual Meeting 2023
April 14 – 19 | Orlando, FL | Booth #2442

Labcorp Oncology is uniquely positioned to power better decisions in oncology, providing solutions that support each step of the care continuum. Speak to our diagnostic team about our comprehensive portfolio from centralized testing to kitted solutions for screening, diagnosis and prognosis, or meet with our drug development teams about our global oncology-specific expertise that helps advance development of cancer diagnostics, drugs and devices through the full drug development continuum with speed and efficiency.

 

  • Join our Spotlight Theater

    The power of ctDNA testing in therapy selection and recurrence monitoring 

    Liquid biopsy represents a transformation in the management of oncology patients given its potential to detect, characterize and monitor cancers earlier than can be achieved with conventional modalities. Due to its noninvasive nature, availability and accessibility, liquid biopsy offers an alternative sampling option when tissue is unavailable or insufficient.  

    In this symposium, we demonstrate the following:

    • The utility of an NGS-based ctDNA testing approach for therapy selection in advanced cancers   
    • Tissue-agnostic treatment response monitoring in patients with metastatic colorectal cancer and its prognostic value in guiding treatment decisions
       

    April 18, 2023
    10:00 - 11:00 AM
    Room: Exhibit Hall Theater C

     

  • Speakers

Mark Sausen

Dr. Mark Sausen, PhD 
Executive Director, Labcorp 

M Kassawneh

Dr. Mohamad Khasawneh, MD 
Leonard Lawson Cancer Center/Pikeville Medical Center
 

  • VIEW OUR POSTERS 
     

    Session Category: Tumor Biology

    #37   A novel technique to preclinically assess the ability of targeted therapies to inhibit both primary and metastatic non-small cell lung carcinoma 
    Erin Trachet
    Session Category: Tumor Biology 
    Session Title: Novel Models of Human Cancer 
    Location: Section 2 
    Poster Board Number: 5 

    #41   Subcutaneous growth and immune cell profiling of BT-474 human breast carcinoma in triple immunodeficient mice from multiple commercial vendors
    Justin Snider 
    Session Category: Tumor Biology 
    Session Title: Novel Models of Human Cancer 
    Location: Section 2 
    Poster Board Number: 9 

    #2402   Fractionated dosing: A more clinically relevant approach to radiotherapy in preclinical tumor models 
    Kerry Ann Bright 
    Session Category: Tumor Biology 
    Session Title: Radiation Sciences 
    Location: Section 3 
    Poster Board Number: 2 

    #4654   Differential immunomodulation following checkpoint blockade in the orthotopic ID8-luc ovarian model 
    Sheri Barnes 
    Session Category: Tumor Biology 
    Session Title: Inflammation and Tumor Progression 
    Location: Section 5 
    Poster Board Number: 11 

    #4561   3D Reconstructed Pancreas: A model capturing the unique tumor microenvironment and stromal architecture of pancreatic cancer 
    Dr. Uihlein (Predictive Oncology) 
    Session Category: Tumor Biology 
    Session Title: 3D and Tissue Recombinant Models 
    Location: Section 2 
    Poster Board Number: 12 

    #5945   Transcriptional analysis of TME in MC38 colon carcinoma model following checkpoint inhibition 
    Priyanka Singh 
    Session Category: Tumor Biology 
    Session Title: Tumor-Stromal Cell (Including Immune Cell) Interactions and Therapy Responses 
    Location: Section 7 
    Poster Board Number: 6 

    Session Category: Experimental and Molecular Therapeutics 

    #589   Long-term acclimation of target cell lines to tumor microenvironment culture condition provides mechanistic insights into cell therapy effectiveness 
    James Lim (Xcell Bio)
    Session Category: Experimental and Molecular Therapeutics 
    Session Title: Targeting the Tumor Microenvironment 
    Location: Section 20 
    Poster Board Number: 23 

    #2749   Preclinical assessment of chimeric antigen receptor (CAR) T persistence and functionality in the disseminated NALM6-Luc human B cell acute lymphoblastic leukemia (ALL) model 
    Dave Draper 
    Session Category: Experimental and Molecular Therapeutics 
    Session Title: Innovative Assay Technologies 
    Location: Section 17 
    Poster Board Number: 3 

    #2762    Inhibition of Murine Myeloid Suppressor Cells Increases CD8+ T cell Activation in Vitro 
    Anita Zaitouna 
    Session Category: Experimental and Molecular Therapeutics 
    Session Title: Innovative Assay Technologies 
    Location: Section 17 
    Poster Board Number: 16 

    Session Category: Immunology

    #1782   Functional potency assay predicts CAR-T effectiveness in tumor microenvironment 
    Yelena Bronevetsky (Xcell Bio) 
    Session Category: Immunology 
    Session Title: CAR T-cell Therapy 
    Location: Section 22 
    Poster Board Number: 16 

    Session Category: Clinical Research Excluding Trials

    #3358   PLCRC-PROVENC3: Assessing the prognostic value of post-surgery liquid biopsy cell-free circulating tumor DNA in stage III colon cancer patients.
    Carmen Rubio Alarcón
    Session Category: Clinical Research Excluding Trials
    Session Title: PO.CL01.16 - Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 3
    Location: Section 43
    Poster Board Number: 1
     
    #5452   Complimentary use of DNA- and RNA-based NGS assays optimizes detection of clinically relevant translocations for comprehensive genomic profiling

    Rongqin Ren
    Session Category: Clinical Research Excluding Trials
    Session Title: Biomarkers of Therapeutic Benefit 5
    Location: Section 37
    Poster Board Number: 2

    #5587   Ultra-deep targeted sequencing of cell-free DNA and patient-matched white blood cells for treatment response evaluation in patients with metastatic colorectal cancer.
    Iris van ‘t Erve
    Session Category: Clinical Research Excluding Trials
    Session Title: PO.CL01.17 - Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 4
    Location: Section 41
    Poster Board Number: 11

    #5597   Enhanced detection and classification of cell-free DNA alterations through matched normal analyses with PGDx elio plasma complete
    Tonya N. Watkins
    Session Category: Clinical Research Excluding Trials
    Session Title: PO.CL01.17 - Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 4
    Location:  Section 41
    Poster Board Number: 21

    #923   Genomic landscape of patients with non-small cell lung cancer.
    Neeraj Kumar Singh
    Session Category: Clinical Research Excluding Trials    
    Session Title: PO.CL11.01 - Analyses Using Clinical and Genomic Databases
    Location: Section 38
    Poster Board Number: 6

    Session Category: Experimental and Molecular Therapeutics  

    #6220   Development of a mutation profiling NGS assay to facilitate clinical decisions in hematologic malignancies.
    Grant Hogg
    Session Category: Experimental and Molecular Therapeutics        
    Session Title: DNA Repair / Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes / Others
    Location: Section 18
    Poster Board Number: 22

    Session Category: Clinical Trials  

    #CT212   A ctDNA-directed, multi-center phase II study of molecular response adaptive immuno-chemotherapy in patients with non-small cell lung cancer: Analysis of Stage 1 of CCTG BR.36
    Valsamo Anagnostou
    Session Category: Clinical Trials    
    Session Title: PO.CT02.02 - Phase II Clinical Trials 2
    Location: Section 47
    Poster Board Number: 2

     

     

Get Email Updates

Stay current by signing up to receive the latest news and updates on tests and services.